Furthermore, high expression of SOX2, PRRX1, or OCT2 correlates with poor patient outcome and worse survival rate, and therefore these three genes could be therapeutic targets for SETD2‐mutant ccRCC patients. This evidence concerns the gene POU2F2 and nonpapillary renal cell carcinoma.